PRMT5 and Miyoshi myopathy: As p53 −/− cells have been shown to lose sensitivity to melphalan and other classical chemotherapeutic regimens, this observation creates a rationale for evaluating the role of PRMT5 inhibitors in MM patients harbouring p53 defects (Drach et al., 1998; Munawar et al., 2019).